Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18193304 | 1.00 | PDPK1 (0.44) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL20458777 | 0.90 | PDPK1 (0.42) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL18385931 | 0.88 | SLC6A2 (0.41) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL402682 | 0.86 | PDPK1 (0.40) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL26879278 | 0.85 | SLC6A2 (0.44) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL25909886 | 0.84 | BCHE (0.46) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL12118229 | 0.83 | SLC6A2 (0.42) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL20226452 | 0.79 | BCHE (0.45) | SLC6A2BCHEMAPTCYP2C19 | |
| SCHEMBL18193303 | 0.79 | PDPK1 (0.41) | PDPK1MTORSLC6A2BCHEMAPT | |
| SCHEMBL1561047 | 0.79 | SLC6A2 (0.45) | PDPK1MTORSLC6A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | AMICUS THERAPEUTICS INC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9481700-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | ALDOA, FBP1, GALE | PDPK1 1226/4885MTOR 4320/4885SLC6A2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.